RecruitingNCT06909253
Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis
Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis (gMG) Naive to Complement Inhibitors. Prospective, Multicenter, Non-interventional Study (MG-ARCADIA).
Sponsor
AstraZeneca
Enrollment
50 participants
Start Date
May 15, 2025
Study Type
OBSERVATIONAL
Conditions
Summary
The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Adult (aged ≥18 years) patients with gMG, naive to complement inhibitors, receiving ravulizumab treatment in the frames of NDP in Poland.
- Patients willing to participate in the study and signed Informed Consent Form (ICF).
- Vaccination against N. meningitidis
Exclusion Criteria2
- Those who plan to participate in gMG clinical trial on/after the date of first ravulizumab infusion through NDP.
- Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGRavulizumab
Ravulizumab, concentrate for solution for infusion
Locations(14)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06909253
Related Trials
Evaluate the Benefit of Corticoid Sparing in Elderly With Generalized AntiRAch Myasthenia Gravis Treated With IV or SC Efgartigimod
NCT070729881 location
Rituximab EfFicacy IN MyasthEnia Gravis (REFINE)
NCT058688371 location
Markers of Favorable Response to Complement Inhibitors Therapy
NCT064557091 location
Efficacy and Safety of Tocilizumab in the Treatment of Generalized Myasthenia Gravis
NCT050673486 locations
Myasthenia Gravis Foundation of America Global MG Patient Registry
NCT066177411 location